Trump: Coronavirus vaccine likely coming ‘in matter of weeks’
President Trump on coronavirus treatments and plans to distribute the vaccine when it is approved.
American pharmaceutical company Pfizer Inc. touted in its earnings report Tuesday that nearly 36,000 people have received a second vaccination in its coronavirus vaccine phase 2/3 clinical trial that has 42,000 participants.
Continue Reading Below
Pfizer is one of the companies on the cutting edge of a coronavirus vaccine. Earlier in October, the company said it may apply for emergency-use authorization of its vaccine by late November.
Its vaccine candidate was "well tolerated with mild to moderate fever in fewer than 20% of the participants … across all populations," Pfizer said.
Pfizer Inc. (PFE) on Tuesday reported third-quarter profit of $2.19 billion.
PFIZER MAY APPLY FOR EMERGENCY USE OF COVID-19 VACCINE BY LATE NOVEMBER
On a per-share basis, the New York-based company said it had profit of 39 cents. Earnings, adjusted for non-recurring costs, came to 72 cents per share.